Literature DB >> 28867062

Home-based delivery of XR-NTX in youth with opioid addiction.

Hoa T Vo1, Rachael Burgower2, Ilya Rozenberg3, Marc Fishman4.   

Abstract

Early experience with relapse prevention medications in the treatment of opioid addiction in youth has been positive, but barriers to effectiveness and broader adoption have included problems with adherence and retention, and lack of evidence or consensus about implementation. In particular there is relatively little known about either the effectiveness of extended release naltrexone (XR-NTX) in youth, or optimal models of care for its delivery. The purpose of this study is to report on a pilot initiative to improve the effectiveness of XR-NTX by delivering doses at home with assertive outreach to patients enrolled in a community treatment outpatient program. This is a naturalistic case series based on retrospective chart abstractions of 14 young adults (mean age=20.5), who enrolled in the pilot program, and in particular, the 9 who received home-based doses of XR-NTX. They are compared to a historical group of patients (n=21) prior to the pilot, who were referred to receive standard clinic-based doses of XR-NTX. Home-based administration was viewed favorably by patients and families. Although the small sample size is not amenable to statistical analysis, patients in the home based group, compared to the historical clinic-based group, received a greater number of doses overall and over 16 weeks of treatment, had longer retention, and attended similar numbers of clinic-based counseling sessions. These preliminary findings suggest that home-based delivery of XR-NTX and assertive outreach are feasible and promising in this critical target population, may compare favorably to clinic-based treatment as usual, and should be explored further in more rigorous evaluations.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Assertive outreach; Naltrexone; Opioid; Opioid addiction; Opioid use disorder; Youth

Mesh:

Substances:

Year:  2017        PMID: 28867062     DOI: 10.1016/j.jsat.2017.08.007

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  7 in total

1.  Management of Opioid Misuse and Opioid Use Disorders Among Youth.

Authors:  Camille A Robinson; J Deanna Wilson
Journal:  Pediatrics       Date:  2020-05       Impact factor: 7.124

2.  Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.

Authors:  Adam Viera; Daniel J Bromberg; Shannon Whittaker; Bryan M Refsland; Milena Stanojlović; Kate Nyhan; Frederick L Altice
Journal:  Epidemiol Rev       Date:  2020-01-31       Impact factor: 6.222

3.  Young Adults Have Worse Outcomes Than Older Adults: Secondary Analysis of a Medication Trial for Opioid Use Disorder.

Authors:  Marc Fishman; Kevin Wenzel; Jennifer Scodes; Martina Pavlicova; Joshua D Lee; John Rotrosen; Edward Nunes
Journal:  J Adolesc Health       Date:  2020-08-29       Impact factor: 5.012

4.  Treatment Trajectories During and After a Medication Trial for Opioid Use Disorder: Moving from Research as Usual to Treatment as Usual.

Authors:  Marc Fishman; Hoa T Vo; Rachael Burgower; Michael Ruggiero; John Rotrosen; Josh Lee; Edward Nunes
Journal:  J Addict Med       Date:  2020 Jul/Aug       Impact factor: 3.702

Review 5.  Adolescent Substance Use Disorder Treatment: an Update on Evidence-Based Strategies.

Authors:  Matthew C Fadus; Lindsay M Squeglia; Emilio A Valadez; Rachel L Tomko; Brittany E Bryant; Kevin M Gray
Journal:  Curr Psychiatry Rep       Date:  2019-09-14       Impact factor: 5.285

6.  Opioid Use Disorders in Adolescents-Updates in Assessment and Management.

Authors:  Amy M Yule; Rachael M Lyons; Timothy E Wilens
Journal:  Curr Pediatr Rep       Date:  2018-04-25

7.  Becoming our young people's case managers: caregivers' experiences, needs, and ideas for improving opioid use treatments for young people using opioids.

Authors:  Kirsten Marchand; Roxanne Turuba; Christina Katan; Chantal Brasset; Oonagh Fogarty; Corinne Tallon; Jill Fairbank; Steve Mathias; Skye Barbic
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-05-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.